India’s opportunity to build a preventive healthcare economy
India’s strength lies not just in technology availability, but in adoption behaviour
India’s strength lies not just in technology availability, but in adoption behaviour
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Subscribe To Our Newsletter & Stay Updated